August 27, 2018
Source: Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018.
Authors: J.G. Pol, S. Lévesque, S. Workenhe, S. Gujar, F. Le Boeuf, D.R.Clements, J.E. Fahrner, L. Fend, J.C. Bell, K.L. Mossman, J. Fucikova, R. Spisek, L. Zitvogel, G. Kroemer, L. Galluzzi
Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.
